Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Tamsulosin Hydrochloride 0.4 mg Prolonged-release Tablets
NCT07146711Phase 1Active, not recruiting
- Sponsor
- Menarini Group
- Start
- Mar 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tamsulosin in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Menarini Group. Primary endpoints: Maximum Plasma Concentration at Steady State at 7 days, Area Under the Curve Over Dosing Interval at Steady State at 7 days and 1 more. Started Mar 2025; status: active, not recruiting.
02
Drugs
tamsulosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT07146711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07146711.